Tarsus Pharmaceuticals
TARS
73 hedge funds and large institutions have $292M invested in Tarsus Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 8 reducing their positions, and 1 closing their positions.
9,918% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $11K
2,300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 1
288% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more funds holding
Funds holding: 51 → 73 (+22)
31% more capital invested
Capital invested by funds: $222M → $292M (+$69.5M)
12.1% more ownership
Funds ownership: 63.79% → 75.89% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$26.8M |
| 2 |
DM
Deerfield Management
New York
|
+$19.9M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$12.3M |
| 4 |
BlackRock
New York
|
+$8.64M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.1M |
| 2 |
DAM
DLD Asset Management
New York
|
-$547K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$63.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$56.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$52.9K |
TARS Hedge Fund Activity: Q2 2022 in Review
73 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q2 2022, worth a combined $292M — up 31% from $222M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TARS positions and 1 closed out — a net gain of 23 holders — while 31 added to existing stakes and 8 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $26.8M. The largest seller was Vivo Capital, cutting an estimated $10.1M.
- 73 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q2 2022, up from 51 in Q1 2022.
- Funds reported $292M of Tarsus Pharmaceuticals stock for Q2 2022, up 31% quarter-over-quarter.
- 24 funds opened new Tarsus Pharmaceuticals positions in Q2 2022 and 1 closed out, a net change of +23 holders.
- The largest Tarsus Pharmaceuticals buyer in Q2 2022 was Tang Capital Management, an estimated $26.8M added.
- The largest Tarsus Pharmaceuticals seller in Q2 2022 was Vivo Capital, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2022.